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Atrial Fibrillation is Strongly Associated with
Prolonged Hospital Stay After Open Heart
Surgery Even After Correcting for Common
Predictors of Morbidity
Merritt H. Raitt. G. Lee Dolack, Kathy Kino, Brad Hofer. Gust H. Bardy. University of
WaShington. Seattle. WA; Oregon Health Sciences University. Portland. OR
Atrial fibrillation (AF) has been shown to be associated with prolonged hos-
pital stay after open heart surgery. It has been difficult to establish whether
AF is causally related to prolonged hospitalization or is simply a marker for
more complicated patients. We identified 110 patients in sinus rhythm off an-
tiarrhythmic medications prior to open heart surgery who developed at least
6 hours of AF after surgery and compared them to 96 randomly selected
controls who did not develop AI'
Results: Patients that developed AF had a longer mean hospital stay after
open heart surgery than did patients without postoperative AF (11.7 ± B.l vs.
7.2 ± 4.4 days. p < 0.0001, 95% CI 2.7 - 6.3 days). Only 15 patients (14%)
had AF identified as the sole reason for extending their hospitalization at
least one full day 12.5 ± 1.6 days per patient). Nevertheless, after controlling
for history of congestive heart failure, myocardial infarction, or diabetes. age,
ejection fraction. sex, the type of surgery performed, and bypass pump time.
AF remained a highly significant (p < 0.0001) predictor of the duration of
hospitalization after surgery.
ConClusion: The specific treatment of AF alone probably accounts for only
a small portion of the prolonged hospitalization associated with new AF after
open heart surgery. Despite this finding. the significantly prolonged hospital-
izations of patients that develop AF and the powerful predictive value of AF
for explaining prolonged hospital stay even after correcting for other clini-
cal variables suggests that AF is not simply a marker for more complicated
patients but in a causal manner contributes to prolonged hospitalization. Ef-
fective prevention and treatment of AF should significantly shorten the mean
duration of hospitalization after open heart surgery.
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Pravastatin Prevents Restenosis After PlCA of
High Grade Stenotic Lesions - Results of
SHIPS (SHiga Pravastatln Study)
Yasuyuki Nakamura. Osamu Yamaoka. Kazunori Uchida. Naoki Morigami.
Tamotsu Fujita. Teruro Inoue. Toshikazu Fuchi. Masataka Hachisuka.
Hirotsugu Ueshima. Masahiko Kinoshita. SHIPS Group. Shiga University of Medical
Science, Seta, Otsu, Japan
The Shiga Pravastatin Study (SHIPS) is a 5 center randomized, double blind
placebo controlled trial to test whether pravastatin, 10 mg twice daily be-
gun at least 10 days prior to elective PTCA in patients with total cholesterol
(T-Chol) hess than 280 mg/dl can decrease restenosis. The endpoint is a be-
tween group comparison of frequency of restenosis defined as a more than
50% loss of gain at PTCA site at 3 months follow-up by automated quanti-
tative coronary arteriography. 179 lesions 185 pravastatin. 94 placebo) in 124
patients (62 pravastatin. 62 placebo) were randomized. The two groups were
comparable for baseline clinical and angiographic characteristics. T-Chol de-
creased from 204 to 172 mg/dl in pravastatin group (P < 0.001), but not in
placebo (201 vs 202 mg/dl). Although restenosis rate was not different in the
two groups (29.4% in pravastatin vs 39.4% in placebo. P = 0.16) as a whole,
it was reduced to about 1/5 (8.B%) in pravastatin group compared to 44.B%
in placebo (P = 0.0011) when the analysis was restricted to high grade le-
sions (~75% diameter stenosis by automated analysis. which is equivalent
to ~90% stenosis by visual analysis; 34 lesions in pravastatin, 29 lesions in
placebo). The effect of pravastatin in prevention of restenosis in high grade
lesions was equally seen both in the groups with baseline T-Chol of above
(10.5 vs 45.5%, P = 0.029) and below 200 mgldl {6.7 vs 44.4%. P = 0.015}
Conclusion: Pravastatin prevents restenosis after PTCA of high grade le-
sions irrespective of baseline T-Chollevel.
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Use of a Cost Outcome Risk Score to
SimUltaneously Stratify Mortality, Morbidity, and
Cost Outcomes for Cardiac Valve Patients
Gregory L. Kay. Guo-Wen Sun. Curtis A. Prejean. Manuel R. Estioko. The Heart
Institute. The Good Samaritan Hospital, Los Angeles. California
To investigate whether risks in postoperative outcomes (mortality. morbidity
and costs [not charges]) can be simultaneously stratified preoperatively. data
were reviewed for 551 consecutive patients who underwent valve surgery.
Patient age 64.0 (±15.4) years and 43.4% females. There were 279 (50.6%)
aortic valve procedures. 177 (32.1 %) mitral valve procedures. 7 (1.3%) tri-
cuspid valve procedures. BB (16.0%) combined valve procedures, and 15B
(2B.7%) valve plus coronary procedures. The average total hospital stay was
13.7 (±14) days and postoperative stay was 11.0 (±12.6) days. To develop a
cost outcome risk score, multivariate analysis of hospital costs via the Cox
proportional hazards model was applied. This model adjusts for patient's
death. patients's health status at discharge and is not distorted by cost
outliers. Patient age, gender, body surface area, body mass index. surgeon
case-volume, procedural urgency, preoperative ejection fraction. history of
diabetes, infective endocarditis, pulmonary hypertension, history of CABG,
prior MI, and type of procedures were incorporated.
Score N Hospital t Hasp. Total t Hasp. Cardiac t Hospital t
Costs ($) Mortality Mortality Morbidity
2-6.9 72 15.571 0.00 000 2.78
7-11.9 137 18,414 2.92 0.73 13.14
12-17.9 120 23,040 4.17 2.50 20.00
18--27.9 97 27.906 1031 515 31.96
" 28 125 41.605 22040 10040 5280
ALL 551 25.982 853 399 25.59
A Comparison of Preoperative Risk Factors for
Early and Late Hospital Death in Cardiac
Surgeries
Manuel R. Estioko. Guo-Wen Sun. Curtis A. Prejean. Gregory L. Kay. The Heart
Institute. The Good Samaritan Hospital. Los Angeles, California
Influence of preoperative risk factors on hospital mortality in cardiac surg-
eries has been investigated. but no one has identified differences in risk fac-
tors on early (postop day ~ 2) and late death (postop day ~ 3). To explore
proper preventive strategies for each death, data were reviewed in 4351
adult patients who underwent cardiac surgery between 1/1/90 and 6/30/94.
There were 93 (2.14%) early deaths and 171 (4.02%) late deaths in this se-
ries. Patients who died are older (early: 67.8 vs. 64.2, P = 0.002; late: 71.1
vs. 63.9, P < 0.001) Proportion of females is higher in late deaths (41.5%
vs. 29.7%. P = 0.001). but not in early deaths (32.3% vs. 30.2%, P = 0.6).
The early and late mortality are 1.65% and 2.78% for isolated CABGs (n =
3037). 1.82% and 4.0% for isolated valves (n = 713), 3.79% and 9.61 % for
CABG + valve (n = 422), 7.B2% and 12.73% for others (n = 179). To adjust
influence of preoperative risk factors on each type of death. stepwise logistic
regression was applied.
Early Death Late Death
Risk Factor Odds Ratio p Risk Factor Odds Ratio p
Cardiac arrest 5.98 <0.001 Cardiogenic shock 6.93 <0.001
Refuse biood 584 <0.001 Renal disease 5.50 <0.001
Age" 85 years 5.01 0.008 CV disease 4.08 <0.001
Emergency 367 <0.001 MI <30 days 3.36 0.004
Re-operation 285 <0.001 Cardiac arrest 331 <0.001
Rheumatic dis. 279 0.001 Respiratory dis 3.19 <0.001
Preop EF <35% 271 <0.001 Liver disease 3.04 0.051
Hypotension 2.26 0.009 Age" 75 years 2.80 <0.001
MI < 10 days 2.10 0.005 Rheumatic dis. 2.19 0.002
IASP support 1.92 0042 Emergency 1.56 0.035
Age 65-64 years 1.77 0.017 Heart Failure 148 0050
Diabetes 1047 0055
Chronic Isch. HD 0.37 <0.001
t P < 0.001 for testing differences among risk groups. Hospital costs = hospital adjusted
direct costs
ConClusions: 1) When patients are stratified for hospital costs by preoper-
ative risk factors, the same scoring system accurately predicts mortality and
morbidity outcomes. 2) Using this analysis framework. with agreed upon
preoperative risk factors. cost efficiency as well as other outcomes can be
compared across programs, physicians, and geographic regions.
Conclusions: (1) Acute cardiac factors dominate early mortality. (2) Chronic
organ system function is more important in late deaths than in early deaths.
(3) Risk adjusted mortality does not differ significantly in genders.
